Female breast cancer in New South Wales, Australia, by country of birth: implications for health-service delivery. by Roder, D et al.
RESEARCH ARTICLE Open Access
Female breast cancer in New South Wales,
Australia, by country of birth: implications
for health-service delivery
David Roder1* , George W. Zhao1, Sheetal Challam2, Alana Little1, Elisabeth Elder3, Gordana Kostadinovska4,
Lisa Woodland5 and David Currow6
Abstract
Background: NSW has a multicultural population with increasing migration from South East Asia, the Western
Pacific and Eastern Mediterranean.
Objective: To compare cancer stage, treatment (first 12 months) and survival for 12 country of birth (COB)
categories recorded on the population-based NSW Cancer Registry.
Design: Historic cohort study of invasive breast cancers diagnosed in 2003–2016.
Patients: Data for 48,909 women (18+ ages) analysed using linked cancer registry, hospital inpatient and Medicare
and pharmaceutical benefits claims data.
Measurement: Comparisons by COB using multivariate logistic regression and proportional hazards regression with
follow-up of vital status to April 30th, 2020.
Results: Compared with the Australia-born, women born in China, the Philippines, Vietnam and Lebanon were
younger at diagnosis, whereas those from the United Kingdom, Germany, Italy and Greece were older. Women
born in China, the Philippines, Vietnam, Greece and Italy lived in less advantaged areas. Adjusted analyses indicated
that: (1) stage at diagnosis was less localised for women born in Germany, Greece, Italy and Lebanon; (2) a lower
proportion reported comorbidity for those born in China, the Philippines and Vietnam; (3) surgery type varied, with
mastectomy more likely for women born in China, the Philippines and Vietnam, and less likely for women born in
Italy, Greece and Lebanon; (4) radiotherapy was more likely where breast conserving surgery was more common
(Greece, Italy, and Lebanon) and the United Kingdom; and (5) systemic drug therapy was less common for women
born in China and Germany. Five-year survival in NSW was high by international standards and increasing. Adjusted
analyses indicate that, compared with the Australian born, survival from death from cancer at 5 years from
diagnosis was higher for women born in China, the Philippines, Vietnam, Italy, the United Kingdom and Greece.
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Conclusions: There is diversity by COB of stage, treatment and survival. Reasons for survival differences may
include cultural factors and healthier migrant populations with lower comorbidity, and potentially, less complete
death recording in Australia if some women return to their birth countries for treatment and end-of-life care. More
research is needed to explore the cultural and clinical factors that health services need to accommodate.
Keywords: Breast cancer survival, New South Wales, Birth countries
Background
Australia had a high relative survival from breast cancer
at 93% 5 years from diagnosis in 2012–2016 [1, 2]. This
is a marked increase from the corresponding 74% in
1982–87 [3] and was accompanied by a 37% decline at
population level in age-standardized breast cancer mor-
tality [4].
Survival from breast cancer in Australia, as indicated
by the complement of the breast cancer mortality to in-
cidence ratio (1-M/I), is at the high end of the inter-
national scale [5]. This varies across the population,
however, with lower survival at each end of the age
range and in women from lower socioeconomic areas [2,
6]. Screening participation through the “free” national
BreastScreen program, which focuses on women aged
50–74 years, contributes to increases in post-diagnostic
survival [7].
Effects on survival of differences in treatment access
and treatment quality are not well documented although
difficulties in access have been reported for older women
and those from more disadvantaged areas [8]. While
women from culturally and linguistically diverse (CALD)
backgrounds have generally experienced a lower screen-
ing participation, differences in follow-up treatment ac-
cess and quality for these women compared with the
Australian-born are largely unknown [8, 9].
Australia has a multicultural population, reflected in
New South Wales (NSW) where almost a third of the
population live and where the percentage born outside
of Australia has increased to about 28%, with 25% of res-
idents speaking a language at home other than English
[10, 11].
Between 2006 and 2016, the largest increases in popu-
lation size from migration by birthplace applied to
China, India, Nepal, the Philippines, Vietnam and South
Korea [11, 12]. There was also an increase in people
born in Lebanon [12].
Previous studies in NSW and other Australian jurisdic-
tions indicated that compared with the Australian-born,
migrants generally have a lower overall cancer incidence
and mortality, although differences occur by cancer type
and country of origin [13].
Few data exist in Australia on stage of breast cancer at
diagnosis, or of treatment, by COB. Australia-wide
cancer-registry studies have not monitored breast cancer
treatment by COB or cultural background, although
breast cancer treatment was investigated in an earlier re-
gional study within the NSW capital, indicating that
Asian women with node-positive, non-metastatic breast
cancer were more likely to undergo mastectomy and to
receive chemotherapy than non-Asian women [14]. No
differences in exposure to radiotherapy or endocrine
therapy were found in that study but the relevance of re-
sults to NSW overall was unknown [14]. Similarly, the
relevance to NSW overall of data for Arabic-speaking
women at a major Sydney hospital is not known [15].
The New South Wales Cancer Registry (NSWCR) re-
cords COB which shows population diversity [13]. We
have used COB data in this study to investigate differ-
ences in stage (degree of spread), treatment and survival
from breast cancer in NSW women according to
whether born in Australia [9], other countries where
numbers were sufficient for analysis, and for remaining
women, according to whether born in a “mainly English-
speaking” or “mainly non-English speaking” country.
The aim of the study was to analyse data for these
women over a 14-year period using unadjusted and ad-
justed models by COB and other sociodemographic
characteristics (age at diagnosis, socioeconomic status of
residential area) and clinical features at diagnosis (stage
and recorded comorbidity [16]). Differences in stage (de-




A retrospective cohort design was used with linked
NSWCR-recorded invasive breast cancers [16, 17], hos-
pital inpatient [18], universal Medicare and pharmaceut-
ical benefits claims data [19, 20], and death data from
the NSW Register of Births, Deaths and Marriages and
National Death Index [21]. The linkage process used na-
tionally accepted and previously described privacy-
protecting protocols to produce de-identified data for
analysis [22]. Linkage of NSW-based datasets was per-
formed by the Centre for Health Record Linkage
whereas the Australian Institute of Health and Welfare
(AIHW) linked nationally stored data [23]. Probabilistic
data linkage was used plus best-practice data flows and
procedures to protect privacy [24].
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The study cohort comprised women aged 18+ years at
diagnosis with invasive breast cancer (C50: ICD-10) di-
agnosed in 2003–2016, excluding multiple primary can-
cers [23]. Follow-up of cases continued to date of death
or April 30th, 2020, whichever came first. Residents of
four local health districts adjacent to NSW borders (10%
of the NSW population) were excluded as many had
care provided interstate, such that their treatments were
not fully captured in NSW record systems. A sensitivity
analysis of results by stage, treatments and cancer mor-
tality outcomes according to exclusion or inclusion of
these local health districts was undertaken, with similar
results applying (Supplement Table 1).
Cohort members were classified by place of birth as:
Australia; China; Germany; Greece; Italy; Lebanon; New
Zealand; the Philippines; the United Kingdom; Vietnam;
and for remaining members, “other mainly English
speaking” or “mainly non-English speaking” countries re-
spectively, as previously described [24, 25]. Members
without a COB recorded on the NSWCR (6%) were
excluded.
Data collection and recording
The NSWCR uses international cancer registry stan-
dards to record primary cancer site, diagnosis date,
demographic characteristics, stage (degree of spread),
death date and whether death was caused by cancer, and
residential address at diagnosis [17, 26]. Data sources
comprise notifications from hospitals, pathology and re-
lated diagnostic sources, mandated through the NSW
Public Health Act 2010 and the Cancer Institute (NSW)
Act 2003 [17]. The National Death Index at the Austra-
lian Institute of Health and Welfare was used in this
study to obtain death data, particularly for people diag-
nosed in NSW who died in another jurisdiction or in ad-
ministrative districts of NSW not covered in this study
[21]. The NSWCR is administered by Cancer Institute
NSW, which is the NSW Government’s cancer control
agency.
Consistent with conventional registry practice, clinical
examination and test results for periods up to 4 months
from diagnosis were used by the NSWCR to indicate
primary cancer site and most advanced stage [26]. This
was categorised as localised (confined to the site of ori-
gin), regional (had invaded adjacent tissues or regional
nodes), or distant (had spread to distant lymph nodes or
other organ sites), as defined in international guidelines
[17, 24]. Cases with missing data on stage (4%) were
classified as “unknown”. Place of residence was collected
at census collection district level and coded using the
Socio-Economic Index for Areas (SEIFA) which classifies
areas by Index of Relative Socio-economic Disadvantage
(IRSD) in quintiles [27].
Data on treatment by surgery, radiotherapy and/or sys-
temic agents (chemotherapeutic, hormonal, immuno-
logical or targeted) were obtained for the 12months
following diagnosis, with surgery sub-classified as mast-
ectomy or breast conserving. These data were obtained
from linked NSW hospital data and Medicare and
pharmaceutical benefits claims, both for procedures and
pharmaceuticals, using the Australian Classification of
Health Interventions (ACHI 8th edition) or correspond-
ing Medicare and pharmaceutical benefits codes [18–
20]. Hospital inpatient diagnostic codes (ICD-10) were
also collected [18], with a 12-month look-back period,
for deriving the Charlson Comorbidity Index [16, 28].
Statistical analyses
Cross-tabulations were used in initial analyses to de-
scribe cohort characteristics by COB, age at diagnosis
(broadly classified as 18–49, 50–59, 60–69, 70+
years), SEIFA quintile (1–5), diagnostic period (2003–
04, 2005–06, 2007–08, 2009–10, 2011–12, 2013–14,
2015–16), stage (local, regional, distant, unknown),
and recorded Charlson comorbidity index score [26]
(0, ≥1) (Table 1). Characteristics for each COB were
compared with those of the Australian-born, initially
using the Mann-Whitney U Test for ordinal and
Pearson Chi-square test for binary outcomes [29, 30].
These analyses tested the null hypothesis of no differ-
ence in the analysed characteristic with the
Australian-born. The “p values” from statistical testing
used in this context were unadjusted and not inter-
preted literally due to multiple testing. “P < 0.05” was
used simply as a flag with “##” signifying potentially
non-random differences.
Multiple logistic analyses were also undertaken of
COB as a predictor (odds ratio - 95% confidence limits)
for the following dependent variables: non-localised de-
gree of spread (regional and distant), and in the 12
months from diagnosis, any recorded treatment, any sur-
gery, mastectomy, breast conserving surgery, radiother-
apy or systemic therapy respectively (i.e., 7 logistic
models, adjusted for age, comorbidity status, SEIFA
quintile, diagnostic year, and where relevant, stage at
diagnosis (Table 2) [29, 30].
Multivariable proportional hazards regression was
undertaken to determine hazard ratios (95% confidence
limits) for death from cancer up to 5 years from diagno-
sis by COB, adjusting for the same covariables as in the
logistic analyses and for treatment by surgery, radiother-
apy and systemic therapy (Table 2). Follow-up of sur-
vival was from diagnosis to April 30th, 2020, or death,
whichever came first [29, 30].
All multivariate analyses were complete-case analyses
excluding the 4% with unknown stage.
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Results
Descriptive characteristics by country of birth
(unadjusted)
Compared with Australian women as the reference cat-
egory, the following differences were found that were
potentially non-random, i.e., flagged as “##”, as described
in the Methods (see Table 1):
 A younger age distribution at diagnosis presented
for women born in China, Lebanon, New Zealand,
the Philippines, Vietnam, and other “mainly English
speaking” and “mainly non-English speaking” coun-
tries of birth; and an older age distribution for
women born in Germany, Greece, Italy, and the
United Kingdom.
 A greater socioeconomic disadvantage was evident
for women born in China, Greece, Italy, Lebanon,
the Philippines, Vietnam, and “other mainly non-
English speaking” countries; and less disadvantage
for women born in New Zealand, the United King-
dom, and “other mainly English-speaking” countries.
 Less recent diagnostic years applied for women
born in Germany and the United Kingdom; and
more recent diagnostic years for women born in
China, Lebanon, the Philippines, Vietnam, and
“other mainly non-English speaking” countries.
 More localised stage was not observed for any
country category, but less localised stage was evident
for women born in Greece, Italy, Lebanon, and
“other mainly non-English speaking” countries.
 More frequent recording of comorbidity applied for
women born in Italy and less frequent recording of
comorbidity for women born in China, the
Philippines, and “other mainly non-English speaking”
countries. Women born in Vietnam also recorded
comorbidity less frequently, but the number of
Table 2 Adjusted odds ratios for non-localised (regional and distant) stage of breast cancers at diagnosis by country of birth; New
South Wales 2003–2016a
Predictor Number (%) with non-localised stage (total 21,630, out of 46,
779)
aOR non-localised (95% confidence
limits)
Country of birth Australia (ref.) n = 13,773 (45.4) 1.000
China (mainland) n = 484 (46.3) 0.967 (0.853,1.095)
Germany n = 212 (49.3) 1.249 (1.031,1.512)
Greece n = 251 (50.0) 1.301 (1.090,1.553)
Italy n = 374 (51.0) 1.328 (1.146,1.539)
Lebanon n = 326 (55.2) 1.400 (1.186,1.651)
New Zealand n = 476 (47.4) 1.038 (0.915,1.179)
Philippines n = 367 (47.8) 1.050 (0.908,1.213)
United Kingdom n = 1478 (44.8) 1.005 (0.935,1.081)
Vietnam n = 217 (45.0) 0.862 (0.717,1.036)
Other mainly English. Speaking n = 393 (46.9) 1.079 (0.939,1.239)
Other mainly non-English speaking n = 3279 (48.6) 1.123 (1.064,1.184)
Age at diagnosis (years) 18 to 49 (ref.) n = 6348 (53.8) 1.000
50–59 n = 5631 (45.6) 0.714 (0.678,0.751)
60–69 n = 4753 (40.0) 0.564 (0.535,0.594)
70+ n = 4898 (45.7) 0.699 (0.663,0.738)
SEIFA SES Disadvantage 1 (most) (ref.) n = 4008 (48.0) 1.000
2 n = 4057 (47.2) 0.960 (0.904,1.021)
3 n = 4048 (45.8) 0.899 (0.847,0.956)
4 n = 4517 (46.3) 0.916 (0.863,0.973)
5 (least) n = 5000 (44.5) 0.848 (0.801,0.899)
Year of diagnosis Continuous (2003–16) n = 21,630 0.995 (0.991,1.000)
Comorbidity Index
(Charlson)
0 (ref.) n = 20,979 (46.1) 1.000
> 0 n = 651 (50.3) 1.238 (1.106,1.385)
aFemale cases only – 95.6% with treatment details; Multivariate logistic regression adjusted for age, SES, diagnostic year and comorbidity; Excludes multiple
primary cancers and local health districts bordering other states/territories (see text)
aOR adjusted odds ratio, SEIFA SES Socio-Economic Indexes for Areas, ref reference
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women affected is not presented due to small cell
size (n < 5).
Country of birth as a predictor of stage (adjusted)
Multiple logistic analyses indicated an elevated adjusted
odds ratio (aOR) of non-localised (regional and distant)
stage for women born in Germany, Greece, Italy,
Lebanon and “other mainly non-English speaking” coun-
tries (Table 2). Recorded comorbidity was also associ-
ated with an elevated aOR for non-localised stage
whereas a lower aOR was associated with lower residen-
tial disadvantage (higher SES), older age of 50+ years,
and although the difference was small (approximate 6%
across the study period), potentially with a more recent
diagnostic year at aOR 0.995 (0.991–1.000).
Results from supplementary analysis comparing COB
with Australia were similar, irrespective of inclusion or
exclusion of local health districts adjacent to NSW bor-
ders (Supplement Table 1).
Country of birth as a predictor of treatment (first 12
months)
Any treatment (surgery, radiotherapy, systemic therapy)
Unadjusted analysis showed most women born in
Australia (98.5%) were recorded as having treatment, as
was the case for women born in Lebanon. The percent-
age having any treatment had a narrow range from
97.6% (“other mainly non-English speaking” countries)
to 98.9% (the Philippines). When adjusted for sociode-
mographic and clinical variables, the aOR (95% confi-
dence limits) differed from the Australian-born as the
reference category for three country categories with a
lower aOR for women born in China, New Zealand, and
“other mainly English-speaking” countries. Other differ-
ences included a low aOR for any treatment for distant
compared with localised spread and presence of re-
corded comorbidity. Women living in the highest socio-
economic (least disadvantaged) areas had a higher aOR
for any treatment compared with women from the most
disadvantaged areas. A lower likelihood of any treatment
was also indicated with older age.
Supplementary analysis comparing results by COB
showed similar results irrespective of inclusion or exclu-
sion of local health districts adjacent to NSW borders
(Supplement Table 1).
Any surgery
Surgery was the most common treatment, applying to
91.6% of Australian-born women and ranging by COB
category from 87.6% (Greece) to 95.2% (Vietnam). After
adjustment for other sociodemographic and clinical vari-
ables, only women born in “mainly non-English speak-
ing” countries had a different aOR for surgery that was
lower than for the Australian-born (Table 3). Lower
aORs also applied for older age at diagnosis, more recent
diagnostic year, regional and distant compared with
localised stage at diagnosis, and presence of recorded co-
morbidity (Table 3). Compared with the most disadvan-
taged quintile, women living in less disadvantaged areas
(quintiles 2–5) had elevated odds ratios, peaking at 1.484
(1.296, 1.700) for the least disadvantaged (highest SES)
quintile.
Supplementary analysis comparing results by COB
showed little differences irrespective of inclusion or ex-
clusion of local health districts adjacent to NSW borders
(Supplement Table 1).
Mastectomy
Of Australian-born women, 38.3% had a mastectomy,
with the percentage ranging from 30.7% (women born in
Lebanon) to 49.0% (women born in China and Vietnam).
Compared with Australian-born, and after adjusting for
sociodemographic and clinical variables, the aOR for
having a mastectomy was lower for women born in
Greece, Italy, Lebanon and the United Kingdom, but
higher for women born in China at 1.625 (1.430, 1.846),
the Philippines at 1.477 (1.273, 1.714), and Vietnam at
1.542 (1.278, 1.859) (Table 3). Other variables associated
with mastectomy after adjustment (aOR) included lower
odds for more recent diagnostic years and recorded co-
morbidity, but a higher aOR for older age and regional
compared with localised stage.
Breast conserving surgery (BCS)
The proportion of Australian-born women having BCS
was 53.2%, varying from 43.0% (China) to 61.1%
(Lebanon). After adjusting for other sociodemographic
and clinical variables, the aOR for having BCS was lower
than for the Australian-born for women born in China
at 0.605 (0.531, 0.689), the Philippines at 0.693 (0.596,
0.807), and Vietnam at 0.643 (0.532, 0.778); and higher
than for the Australian-born for those born in Greece at
1.254 (1.073, 1.516), Italy at 1.403 (1.198, 1.644),
Lebanon at 1.666 (1.393, 1.994), and the United King-
dom at 1.080 (1.001, 1.167) (Table 3). A lower aOR also
applied for older age at diagnosis, recorded comorbidity,
and compared with localised stage at diagnosis, regional
and distant stage, and a higher aOR for more recent
diagnostic years. Compared with the most disadvantaged
quintile, women living in the less disadvantaged areas
(quintiles 2–5) had elevated aORs, for BCS peaking at
1.158 (1.090, 1.232) for the least disadvantaged (highest
SES) quintile 5.
Supplementary analysis comparing results by COB
showed little differences irrespective of inclusion or ex-
clusion of local health districts adjacent to NSW borders
(Supplement Table 1).
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Radiotherapy
The proportion of women having radiotherapy varied
with surgery type from 39.2% for those having a
mastectomy to 89.1% for those having BCS. Overall,
the proportion of women having radiotherapy was
68.2% for all women in aggregate. This varied by
COB with 65.0% for the Australian-born and ranging
from 58.0% for China to 76.1% for women born in
Lebanon. Compared with the Australian-born, a lower
aOR for radiotherapy applied to women born in
China at 0.610 (0.535, 0.695), the Philippines at 0.646
(0.555, 0.752), and Vietnam at 0.646 (0.534, 0.781);
whereas a higher aOR applied to women born in
Greece at 1.313 (1.076, 1.603), Italy at 1.431 (1.210, 1.692),
Lebanon at 1.518 (1.242, 1.857) and the United Kingdom
at 1.130 (1.042, 1.226). Older women were less likely to
have radiotherapy while higher use of radiotherapy was in-
dicated for regional compared with local spread of disease
and less disadvantaged quintiles 2–5 than quintile 1, peak-
ing at 1.309 (1.228, 1.396) for quintile 5 (least disadvan-
taged). Cancers with distant spread were less likely to have
radiotherapy than localised cancers. Comorbidity was also
associated with a lower likelihood of radiotherapy
(Table 3).
Supplementary analysis comparing results by COB
showed little differences irrespective of inclusion or
Table 4 Adjusted hazard ratios for death from cancer following female breast cancer diagnosis by country of birth; New South
Wales 2003–2016a
Predictor Number of cancer deaths (%) for follow-up period (total 6023 deaths
out of 46,779 cases)
aHR death from cancer (95%
confidence limits)
Country of birth Australia (ref.) n = 4129 (13.6) 1.000
China (mainland) n = 73 (7.0) 0.597 (0.467,0.762)
Germany n = 70 (16.3) 0.957 (0.743,1.232)
Greece n = 66 (13.1) 0.634 (0.491,0.820)
Italy n = 125 (17.1) 0.795 (0.652,0.970)
Lebanon n = 71 (12.0) 0.869 (0.681,1.108)
New Zealand n = 101 (10.0) 0.922 (0.745,1.140)
Philippines n = 54 (7.0) 0.698 (0.540,0.902)
United King. n = 460 (13.9) 0.880 (0.783,0.991)
Vietnam n = 25 (5.2) 0.469 (0.282,0.780)
Other mainly English- speaking n = 87 (10.4) 1.013 (0.810,1.268)
Other mainly non-English speaking n = 762 (11.3) 0.787 (0.720,0.859)
Age at diagnosis (18 to
80+ years)
Continuous n = 6023 (12.9) 1.066 (1.063,1.070)
SEIFA SES Disadvantage 1 (most) (ref.) n = 1419 (17.0) 1.000
2 n = 1335 (15.5) 0.946 (0.866,1.034)
3 n = 1158 (13.1) 0.895 (0.820,0.977)
4 n = 1143 (11.7) 0.835 (0.764,0.912)
5 (least) n = 968 (8.6) 0.684 (0.624,0.750)
Year of diagnosis (2003 to
2016)
Continuous (2013–16) n = 6023 (12.9) 0.964 (0.957,0.972)
Stage (degree of spread) Local (ref.) n = 1565 (6.2) 1.000
Regional n = 2747 (14.8) 2.921 (2.739,3.115)
Distant n = 1711 (54.9) 7.115 (6.485,7.807)
Comorbidity Index
(Charlson)
0 (ref.) n = 5392 (11.9) 1.000
> 0 n = 631 (48.8) 1.958 (1.727,2.219)
Treatment received (1st
round)
Surgery n = 4167 (9.5) 0.285 (0.263,0.308)
Radiotherapy n = 2779 (8.9) 0.768 (0.724,0.814)
Systemic n = 4778 (12.2) 0.649 (0.60,0.702)
aAdjusted for age at diagnosis, SES, year of diagnosis, stage, comorbidity and treatment; Multivariate proportional hazard regression (see text) Excludes multiple
primary cancers and local health districts bordering other states/territories. Date of censoring of live cases 5 years postdiagnosis or April 30th 2020, whichever
came first (see text)
aHR adjusted hazards ratio, SEIFA SES socio-economic indexes for areas socio-economic status, ref reference
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exclusion of local health districts adjacent to NSW bor-
ders (Supplement Table 1).
Systemic therapy
The proportion of women having systemic therapy
tended to be higher for women having a mastectomy
(87.7%) than BCS (81.6%). Overall, the proportion of
women having systemic therapy was 84.2% for all
women in aggregate. This varied by COB with 83.7% of
Australian-born having systemic therapy and with a
range from 77.3% (Germany) to 86.3% (Lebanon). Com-
pared with the Australian born, the aOR for systemic
therapy was lower for women born in China at 0.715
(0.605, 0.845), Germany at 0.683 (0.535, 0.871), and
“other mainly non-English speaking” countries at 0.801
(0.745, 0.863). The aOR for systemic therapy was also
lower at older ages and where comorbidity was recorded,
but higher for upper socioeconomic quintiles 4 and 5
compared with the lowest quintile 1, and for more re-
cent diagnostic years. Compared with localised stage at
diagnosis, the aOR for systemic therapy was higher for
regional stage at 4.277 (4.007, 4.565) and distant stage at
2.356 (2.111, 2.631).
Supplementary analysis comparing results by COB
showed little differences irrespective of inclusion or ex-
clusion of local health districts adjacent to NSW borders
(Supplement Table 1).
Country of birth as a predictor of cancer death
The five-year survival from death Australian-born pa-
tients was 84.1%, varying from 79.8% (Italy) to 93.6%
(Vietnam). Compared with the Australian-born, the ad-
justed risk of cancer death (hazard ratio) within 5 years
of diagnosis was lower for women born in China at
0.597 (0.467,0.762), Greece at 0.634 (0.491,0.82), Italy at
0.795 (0.652,0.97), the Philippines at 0.698 (0.54,0.902),
the United Kingdom at 0.880 (0.783,0.991), Vietnam at
0.469 (0.282,0.78), and “other mainly non-English speak-
ing” countries at 0.787 (0.72,0.859) (Table 4). Other pre-
dictors of a lower risk of cancer death (hazard ratio)
after adjusting for sociodemographic and clinical charac-
teristics were: (a) compared with the lowest socioeco-
nomic residential area (quintile 1), for higher
socioeconomic quintiles 3–5 with the lowest adjusted
hazards ratio applying for the highest quintile 5 at 0.684
(0.624,0.75), and for more recent diagnostic years. By
comparison, other predictors of higher adjusted hazard
ratio (aHR) included: older age at diagnosis, recorded
comorbidity, and compared with localised cancer, re-
gional stage at 2.921 (2.739,3.115) and distant stage at
7.115 (6.485,7.807). Receiving surgical treatment was as-
sociated with a lower aHR of 0.285 (0.263,0.308), com-
pared with 0.768 (0.724,0.814) for radiotherapy and
0.649 (0.60,0.702) for systemic therapy.
Supplementary analysis comparing results by COB
showed little differences irrespective of inclusion or ex-
clusion of local health districts adjacent to NSW borders
(Supplement Table 1).
Discussion
Sociodemographic trends for women in NSW diagnosed
with breast cancer, as presented in this study, have par-
alleled Australian immigration patterns with increasing
numbers of migrants from China, the Philippines,
Vietnam, and Lebanon [10, 11]. There were higher per-
centages of women from European birth countries such
as Germany and the United Kingdom in the earlier diag-
nostic years, and higher percentages from China, the
Philippines, Vietnam and Lebanon in the more recent
years. A difference by age at diagnosis was also evident,
with patients from Germany, Greece, Italy, and the
United Kingdom tending to be older and those from
China, the Philippines, Vietnam and Lebanon tending to
be younger. This pattern reflects the migration compos-
ition to Australia with large numbers of migrants from
Europe after World War II [10, 11].
Socioeconomic disadvantage appeared to be more pro-
nounced for patients born outside of Australia, including
in China, the Philippines, Vietnam and Lebanon, and for
those born in Italy and Greece. These patterns have im-
plications for service provision if services are to meet the
cultural and language requirements of NSW breast can-
cer patients. A positive feature of those born outside of
Australia (e.g., in China, the Philippines, Vietnam, and
“other mainly non-English speaking” countries) was less
evidence of comorbidity. While this may reflect varia-
tions in reporting due to differences in culture, health
beliefs and practices, it may also reflect health require-
ments at time of migration, leading to selection of the
more resilient who could better withstand comprehen-
sive cancer treatments and associated toxicities [31].
Predictably non-localised stage at diagnosis was associ-
ated with increased risk of cancer death in the five years
following diagnosis. Reasons for the lower adjusted risk
of non-localised disease in the least disadvantaged
(upper SES) areas require investigation, including the
possible roles of higher health literacy and more active
health-seeking behaviour. A need for more active pro-
motion of early-detection in women from the more dis-
advantaged areas, and women born in Greece, Italy,
Lebanon, and “other mainly non-English-speaking”
countries, is apparent from this study. Many of the older
women from these countries migrated after World War
II and are more likely to have lower levels of education,
and lower health literacy. They also may have less famil-
iarity with the health system and roles of health profes-
sionals, and when seeking services, face additional
financial, cultural, language and social barriers. Barriers
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may be increased if older women revert with increasing
age to their original language. BreastScreen records
should be examined to assess the contribution of lower
screening coverage to elevated numbers of women with
non-localised cancers by COB [2].
Meanwhile the lower proportion of non-localised
breast cancer stage from age 50 years may reflect the cu-
mulative effects on stage of population screening, with
active recruitment from age 50 years [7, 32]. Also, pre-
menopausal women can have more aggressive breast
cancers that present at a later symptomatic stage, which
could have affected these age differences.
Mastectomies were more common in women from
China, the Philippines and Vietnam, whereas breast con-
serving surgery was more common in women from
Greece, Italy and Lebanon. Again, cultural factors may
have played a part in these differences, including in
some instances, a lower trust in the health system and
stronger reliance on collective decision-making within
families. Our hypothesis is that differences in breast size
also may have contributed, but substantiating inter-
national data are lacking [33].
Older women were more likely to have a mastectomy
and less likely to have breast conserving surgery. Again,
this may be a cultural effect or reflect a lower interest in
breast retention for cosmetic reasons in older age. Also,
some older women, particularly those from country re-
gions, may prefer to have a mastectomy to avoid the need
to travel to urban centres for adjuvant radiotherapy, as
recommended for most women following breast conserv-
ing surgery [34]. The finding that women from the most
disadvantaged residential areas were less likely to have
breast conserving surgery is consistent with earlier re-
search evidence [34]. Anecdotally some women reportedly
prefer mastectomy because they believe it is more likely to
clear the cancer [34]. Predictably mastectomy was less
common for cancers of localised and distant stage,
whereas breast conserving surgery was less common for
regional and distant stage. Meanwhile recorded comorbid-
ity was associated with a lower likelihood of surgery, both
mastectomy and breast conserving surgery.
While exposures to radiotherapy and systemic therapy
were analysed as discrete entities to indicate overall
levels of exposure by country of birth, sub-analyses pre-
dictably indicated exposure to radiotherapy to be higher
in BCS cases (89%) than those having a mastectomy
(39%). The difference was less marked for systemic ther-
apy (88% exposure for mastectomy v. 82% for BCS).
Overall, radiotherapy was less likely for women from
China, the Philippines and Vietnam which accompanied
a lower exposure to breast conserving surgery. By com-
parison women from Greece, Italy, the United Kingdom
and Lebanon were more likely to have radiotherapy.
Likelihood of radiotherapy was also lower in older
women and those with recorded comorbidity, which
may reflect an increased frailty and lack of resilience to
travel to radiotherapy centres and to withstand treat-
ment. The potential to further increase support net-
works to access radiotherapy services should be
considered, including among the socially isolated, older
people who lack carers, and multicultural people who do
not speak English and whose family networks live out-
side of Australia.
Women from the least disadvantaged areas were more
likely to have radiotherapy which is consistent with their
higher use of breast conserving surgery. Differing health
beliefs may also impact on uptake of radiotherapy and
systemic therapy.
Overall, systemic therapies were less likely to be used
by women born in China and Germany, older women,
and those with recorded comorbidity. Women from
more disadvantaged areas tended to have less exposure
to systemic therapy. The reasons require further study.
Predictably, systemic therapy was more commonly used
for non-localised stage.
Survival from cancer was lower in older age, those
reporting more comorbidity, and more non-localised
stage, and higher in the least disadvantaged, which ac-
cords with previous study results [2, 6]. The association
of lower survival with treatment, particularly surgery, is
plausible.
The higher survival for women who migrated to
Australia from China, the Philippines, Vietnam and
“other mainly non-English speaking” countries was un-
expected. Several possible explanations exist. As an ob-
servational study using routinely collected data, we
suspect that residual confounding may have occurred
from a range of sociodemographic and clinical factors
due to insufficient measurement precision or from cul-
tural and other health-related confounders for which we
had no data. Other possible explanations include health
requirements for acceptance of migrants to Australia
which may predispose to acceptance of those with
greater health resilience [31]. Also missing death data
may have contributed if some migrants returned to their
birth countries in the terminal stages such that their
deaths were not recorded in Australia. Further research
with customized data is needed to explore these possibil-
ities, as indicated in the Discussion.
Regarding loss of 10% of cases by excluding border
local health districts with potential for interstate treat-
ment, sensitivity analysis indicated that this had little ef-
fect on results. Of 77 comparisons of effects by country
of birth (Supplement Table 1), 70 gave similar results
based on 95% confidence limits, and the few differences
found were small, indicating reliability of results.
This study has benefited from access to data from a
high-quality population-based registry extended through
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data linkage to include hospital inpatient and health in-
surance data to indicate clinical management and indica-
tors of comorbidity.
Limitations include incompleteness of data on services
provided in non-admitted outpatient settings in public
hospitals. We consider that key surgical and radiother-
apy data would have been captured, plus systemic ther-
apy data for care provided in inpatient settings and in
private hospital outpatient and out-of-hospital environ-
ments, which are generally covered by universal Medi-
care benefits insurance for both procedures and
pharmaceuticals. Another limitation was exclusion of
10% of breast cancers due to place of residence being in
local health districts adjacent to the NSW border where
potential existed for interstate public hospital treatment
that would not have been recorded in NSW data sys-
tems. Lack of data on language spoken at home or re-
quests for interpreter services was also a limitation as
these features can be strong markers of cultural
diversity.
Often odds ratios and hazard ratios have been re-
ported as indicators of potential non-random differences
when divergences from Australian-born as the reference
category were small. Some divergences were small be-
cause small units of measurement were used (e.g., single
years for age and calendar year). In other instances, the
effect of COB on outcomes could have been diluted sub-
stantially depending on time of arrival in Australia (e.g.,
whether during childhood or in adulthood closer to the
breast-cancer diagnosis date). For this reason, all poten-
tially non-random differences, however small, have been
reported and interpreted as flagging differences of po-
tential importance for consideration and further
investigation.
Conclusions
These data indicate cultural diversity in stage, type of
surgical treatment, exposure to radiotherapy and sys-
temic drug therapy, and survival from cancer. Reasons
may include cultural factors and migration health re-
quirements. This and differences in reporting may ex-
plain lower reported comorbidity levels, and potentially
less complete death recording in Australia if some
women born outside of Australia were to return to their
birth countries for treatment and end-of-life care and
die there. More research is needed to investigate these
and other possible explanations. Meanwhile, results illus-
trate the sociodemographic, cultural and clinical diver-
sity of women with breast cancer in NSW and
associations with prognosis, clinical care and outcomes
by COB. This diversity presents challenges that NSW
health services are addressing and need to be accommo-
dated. At present, survival from breast cancer in NSW is
at the high end of the international scale and increasing.
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